|1.||Banik, Naren L: 3 articles (02/2013 - 12/2006)|
|2.||Ray, Swapan K: 3 articles (02/2013 - 12/2006)|
|3.||Yokozawa, Takako: 3 articles (08/2009 - 04/2004)|
|4.||Yang, Chung S: 3 articles (03/2007 - 09/2005)|
|5.||Huang, Yuhui: 2 articles (09/2015 - 04/2012)|
|6.||Kumazoe, Motofumi: 2 articles (09/2015 - 04/2012)|
|7.||Kim, Yoonhee: 2 articles (09/2015 - 04/2012)|
|8.||Tachibana, Hirofumi: 2 articles (09/2015 - 04/2012)|
|9.||Tsukamoto, Shuntaro: 2 articles (09/2015 - 04/2012)|
|10.||Yamashita, Shuya: 2 articles (09/2015 - 04/2012)|
01/01/2015 - "Epigallocatechin 3-gallate ameliorates bile duct ligation induced liver injury in mice by modulation of mitochondrial oxidative stress and inflammation."
06/19/2010 - "Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. "
01/01/2015 - "Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice."
07/01/2009 - "To test the influence of 1000 mg of quercetin (Q) with or without 120 mg of epigallocatechin 3-gallate (EGCG), 400 mg of isoquercetin, and 400 mg of eicosapentaenoic acid and docosahexaenoic acid (Q-EGCG) on exercise performance, muscle mitochondrial biogenesis, and changes in measures of immunity and inflammation before and after a 3-d period of heavy exertion. "
06/01/1992 - "Studies with individual polyphenolic compounds in green tea indicated that topical application of (-)-epigallocatechin gallate, (-)-epigallocatechin and (-)-epicatechin gallate inhibited TPA-induced inflammation in mouse epidermis."
03/10/2011 - "Since (-)-epigallocatechin 3-gallate (EGCG) has shown potent chemopreventive efficacy for PCa, we designed and developed novel targeted NPs in order to selectively deliver EGCG to cancer cells. "
01/01/2013 - "Epigallocatechin 3-gallate (EGCG) has cytotoxic effects in many cancer cells. "
09/01/2009 - "EGCG [(-)-epigallocatechin-3-gallate] has shown its antitumor ability and perhaps a potential regimen for cancer patients. "
12/15/2000 - "We identified (-)-epigallocatechin 3-O:-gallate, as a potent inhibitor of religation by mammalian topoisomerase (IC(50) of 26 nM), potentially explaining the anti-cancer properties previously attributed to this compound. "
01/01/2013 - "The preclinical study thus suggests that the potential medicinal application of SS for inhibiting cancer LDH-A activity and the possibility to consider epigallocatechin as a lead compound to develop LDH-A inhibitors. "
|3.||Breast Neoplasms (Breast Cancer)
08/01/2011 - "A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells."
01/01/2013 - "In vivo study also demonstrated that epigallocatechin could significantly inhibit breast cancer growth, HIF-1α/LDH-A expression and trigger apoptosis without bringing toxic effects. "
12/01/2010 - "Plasma levels of (-)-epigallocatechin (EGC), (-)-epicatechin (EC), (-)-epigallocatechin-3-gallate (EGCG), and (-)-epicatechin-3-gallate (ECG) were measured, and the odds ratio (OR) of breast cancer according to plasma level was estimated using a conditional logistic regression model. "
04/21/2006 - "Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. "
12/01/2002 - "(-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts."
|4.||Diabetic Nephropathies (Diabetic Nephropathy)
08/01/2009 - "In our previous study, epigallocatechin 3-O-gallate exhibited protective effects against renal damage in a rat model of diabetic nephropathy. "
10/01/2006 - "As a further study, we examined whether (-)-epigallocatechin 3-O-gallate (EGCg), the main polyphenolic compound, could ameliorate the development of diabetic nephropathy. "
10/01/2006 - "Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats."
10/01/2014 - "We investigated the protective impacts of (-)-epigallocatechin 3-O-gallate (EGCG) against streptozotocin (STZ)-induced diabetic nephropathy in mice. "
|5.||Colonic Neoplasms (Colon Cancer)
12/01/2013 - "In the present study we found that the sensitivity of colon cancer cells to methylation plays a role in its response to alternative therapy involving the green tea polyphenol, epigallocatechin 3-gallate. "
12/01/2013 - "Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells."
11/20/2009 - "Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide."
04/01/1998 - "The green tea catechins (-)-epigallocatechin-3-gallate (EGCG) and (-)-epigallocatechin (EGC) displayed strong growth inhibitory effects against lung tumor cell lines H661 and H1299, with estimated IC50 values of 22 microM, but were less effective against lung cancer cell line H441 and colon cancer cell line HT-29 with IC50 values 2- to 3-fold higher. "
01/01/2012 - "Antiproliferative and apoptotic effects triggered by Grape Seed Extract (GSE) versus epigallocatechin and procyanidins on colon cancer cell lines."
|2.||epigallocatechin gallate (epigallocatechin-3-gallate)
|7.||NF-kappa B (NF-kB)
|10.||Catechin (Z 7300)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)